News 2011 ›  2011-01-26
Nexstim on a roll

 

2011-12-01
2011-11-30
2011-11-24
2011-11-22
2011-11-17
2011-11-16
2011-11-09
2011-10-26
2011-10-20
2011-10-07
2011-10-03
2011-09-22
2011-09-20
2011-09-15
2011-09-09
2011-07-06
2011-06-27
2011-06-21
2011-06-17
2011-06-16
2011-06-07
2011-06-06
2011-06-01
2011-05-31
2011-05-25
2011-05-19
2011-05-17
2011-05-16
2011-03-03
2011-03-01
2011-02-11
2011-02-02
2011-02-01
2011-01-27
2011-01-26
2011-01-17
2011-01-05

2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

 

2011-01-26
Nexstim on a roll

Non-invasive brain diagnostic and therapy technology pioneer, Nexstim has recently raised valuable additional equity financing for its business – adding Lundbeckfond Ventures of Denmark and the Ilmarinen Mutual Pension Insurance Company to the company’s previous venture capital investors:  HealthCap and LSP (Life Sciences Partners), Sitra, and Finnish Industry Investment.

The new financing will enable Nexstim to significantly expand its sales and marketing activities in Europe and take full advantage of its recent FDA clearance for marketing in the US.

Nexstim also intends accelerating development of next-generation solutions for non-invasive neurotherapy in stroke and other neurological conditions that are largely unmet using conventional technologies.

Founded in 2000, Nexstim is a specialist in Navigated Brain Stimulation (NBS), a non-invasive, image-guided transcranial magnetic stimulation (TMS) technique for brain diagnostics and therapy. The Nexstim NBS System is rapidly becoming the new standard for preoperative functional brain mapping prior to neurosurgery on tumours or to treat epilepsy – and is the only direct, non-invasive cortical mapping device cleared for sale in both the US and Europe.
 
Studies have shown that the accuracy of the NBS System is equivalent to that of invasive direct cortical stimulation during actual brain tumour surgery, which has been considered the ‘gold standard’ for locating the motor cortex up until now.

For more on Nexstim, see our latest article or www.nexstim.com.

The ability of Nexstim’s NBS technology to precisely and reproducibly target non-invasive neurostimulation within the brain opens up the potential for new, non-invasive therapy options for a wide range of brain injuries and diseases, including stroke, depression, and pain. Photo courtesy of Nexstim.